Thanks for the consistent updates Q man and all.
The website looks slick; I also read the reimbursement doc that Kick posted. It speaks to the value of Pulse to clinicians in a transparent benefit-focused and understandable way. 'You do this, the patient benefit is this, and you get paid this'. Providing an answer to the all-important question we all ask "What's in it for me?" Speaking $$$ helps with that equation. Sure there is a fiduciary responsibility for Doctors but let's not kid ourselves; it has to make sense to the bottom line or Doctors won't use it. Full stop. It'd be great to see an example case study in that doc for how much better off (profitable) a clinic could be per 100 patients with the use of Pulse, saving time from not needing people in the office as much and extra $$$ from the extra billable revenue.
My one criticism would be around the copy on the website not catering to the general consumer which in fairness may come later. But as a layman (i.e. may not understand what biometrics are essential and their relevance) consumer that wants to be healthier and feel better/not die suddenly, "next generation", "vascular biomarker" or "clinically relevant" do not mean anything. Sure those are good features, but the benefit is nowhere really to be seen. It's all a bit too technical and jargony for me. It'd be great to have in the second fold of the website something like "Pulse monitors X, Y & Z to provide actionable insights on how you can do A (perform better), B (live longer), C (provide heart peace of mind)." The website imagery is on point though and where it needs to be.
Looking forward to more being released in the coming weeks.
- Forums
- ASX - By Stock
- CDX
- CONNEQTHEALTH goes live
CDX
cardiex limited
Add to My Watchlist
2.50%
!
3.9¢

CONNEQTHEALTH goes live, page-10
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $17.49M |
Open | High | Low | Value | Volume |
3.9¢ | 4.0¢ | 3.8¢ | $20.01K | 521.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 75000 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 60000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 75000 | 0.038 |
5 | 677100 | 0.037 |
2 | 263210 | 0.036 |
4 | 515503 | 0.035 |
3 | 382970 | 0.034 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 60000 | 1 |
0.045 | 82414 | 2 |
0.050 | 100000 | 1 |
0.052 | 180000 | 1 |
0.080 | 100799 | 1 |
Last trade - 15.40pm 27/06/2025 (20 minute delay) ? |
Featured News
CDX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online